Phase II Pethema Trial of Alternating Bortezomib and Dexamethasone As Induction Regimen Before Autologous Stem-Cell Transplantation in Younger Patients With Multiple Myeloma: Efficacy and Clinical Implications of Tumor Response KineticsLaura Rosiñol, Joan Bladé, Albert Oriol et al.|Journal of Clinical Oncology|2007Cited by 111
Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple MyelomaAnna Luise Grab, Marc S. Raab, Peter Kim et al.|Cells|2024Cited by 18
SAR442257, a CD38/CD28/CD3 trispecific antibody, potentiates CAR T‐cell activity against large B‐cell lymphomaM. R. Green, L. Wang, Chizitara Okwuchi et al.|Hematological Oncology|2023Cited by 2
P1366: SAR442257, A CD38/CD28/CD3 TRISPECIFIC ANTIBODY, POTENTIATES CAR T-CELL ACTIVITY AGAINST LARGE B-CELL LYMPHOMAPatrick K. Reville, Michael R. Green, Enyu Dai et al.|HemaSphere|2023Cited by 1